Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie
-
Biomed. Pharmacother. · Jan 2019
ReviewArtemisia campestris L.: review on taxonomical aspects, cytogeography, biological activities and bioactive compounds.
Artemisia campestris L. (Asteraceae) is a polymorphic species that consists of many subspecies and varieties. It is known for its medicinal, pharmacological, and culinary properties. This review is undertaken with the aim to highlight some aspects of this plant, specifically the taxonomy, the cytogeography, the phytochemistry with an emphasis on the structure-activity relationship (SAR) of the main bioactive compounds of A. campestris L. in addition to its biological properties and the food control properties. ⋯ Finally, the food preservative ability of the extracts and essential oil obtained from A.campestris L. have been fully discussed. The present review contributes to the literature, by bringing more clarifications about the different aspects of A.campestris L., like taxonomy, cytogeography and biological interests of this species. The SAR approach of some constituents that occur in A.campestris L., gives a solid support that can be used to explore the bioactivity of components isolated from this species, while the preservative properties of this plant can be usefully exploited for the agrifood sector.
-
Biomed. Pharmacother. · Jan 2019
Hsa-let-7g promotes osteosarcoma by reducing HOXB1 to activate NF-kB pathway.
MicroRNA (miRNA) is known to be involved in regulating the proliferation, migration and apoptosis of cancer cells in osteosarcoma. In this study, We aim to explore the expression of hsa-let-7 g and its role in pathogenesis of osteosarcoma. By analyzing clinical data. ⋯ After downregulation of hsa-let-7 g in cell model and animal model, we found that with downregulation of hsa-let-7 g, the proliferation of osteosarcoma cells was significantly reduced, the level of migration and invasion was down-regulated, the cell cycle was inhibited, and cell apoptosis was increased. Through Dual Luciferase Reporter, immunohistochemistry, western blot and other experiments, it was found that hsa-let-7 g down-regulated HOXB1 gene and activated NF-kB pathway to promote the development of osteosarcoma. In conclusion, hsa-let-7 g is highly expressed in osteosarcoma tissues, and high expression of hsa-let-7 g can promote the occurrence of osteosarcoma by down-regulating HOXB1 and activating NF-kB pathway.
-
Biomed. Pharmacother. · Jan 2019
MicroRNA-150 relieves vascular remodeling and fibrosis in hypoxia-induced pulmonary hypertension.
Pulmonary hypertension (PH) is a dangerous disease, featured by pulmonary vascular remodeling. Excessive proliferation of pulmonary artery smooth muscle cells (PASMCs) and pulmonary artery endothelial cells (PAECs) plays crucial roles in this process. MicroRNA-150 (miR-150) level has been found to be reduced in patients with PH, and correlated with the poor survival. ⋯ Increased NFATc3 expression in response to hypoxia was restrained by miR-150 overexpression in lung tissue and PAMSCs. Finally, miR-150 overexpression inhibited hypoxia-induced proliferation and apoptosis resistance in PAECs. In conclusion, these results indicate that miR-150 protects against hypoxia-induced pulmonary vascular remodeling, fibrosis, abnormal proliferation of PASMCs and PAECs, which suggests miR-150 as a promising therapeutic target for PH.
-
Biomed. Pharmacother. · Jan 2019
Knockdown of lncRNA DLX6-AS1 inhibits cell proliferation, migration and invasion while promotes apoptosis by downregulating PRR11 expression and upregulating miR-144 in non-small cell lung cancer.
Long non-coding RNA (lncRNA) distal-less homeobox 6 antisense 1 (DLX6-AS1) was reported to be dysregulated in lung cancer. However, detailed roles of DLX6-AS1 in the pathogenesis of non-small cell lung cancer (NSCLC) were largely unknown. ⋯ Knockdown of DLX6-AS1 inhibited cell proliferation, migration, invasion and promoted apoptosis by downregulating PRR11 expression and upregulating miR-144 in NSCLC.
-
Biomed. Pharmacother. · Jan 2019
Clinical TrialAmelioration of clinical symptoms of patients with refractory rheumatoid arthritis following treatment with autologous bone marrow-derived mesenchymal stem cells: A successful clinical trial in Iran.
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune arthropathy characterized by synovial hyperplasia leading to functional impairment. Although the exact cause of RA is unknown, there is evidence suggesting the role of T cell subtypes in the pathogenesis of RA. Conventional therapy in some RA patients is associated with mild or severe side effects, and resistance of some patients has been reported to these types of therapy. ⋯ VAS score showed a significant decreasing trend during the follow-up periods. No significant difference was found for serum CRP and anti-CCP levels after the intervention. In conclusion, our data indicated that clinical symptoms were significantly ameliorated following the intravenous injection of autologous bone marrow-derived MSCs to the patients with refractory RA.